

**AstraZeneca Pharma India Limited**

Regd. Office: 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

**FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2011**

Rs. in lakhs (except for number of shares)

Sl. No.	Particulars	3 months ended 30.06.2011	3 months ended 30.6.2010	Year to date figure for 3 months ended 30.06.2011	Year to date figure for 6 months ended 30.06.2010	Previous accounting year (15 months period) ended 31.03.2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	(a) Net sales (net of excise duty)	12,941.82	10,595.60	12,941.82	19,824.01	57,436.20
	(b) Other operating income:					
	- Service income	806.41	495.59	806.41	1,057.97	1,966.30
2	<b>Expenditure</b>					
	(a) (Increase) / decrease in stock-in-trade and work-in-progress	(1,391.62)	(438.51)	(1,391.62)	(839.57)	(1,358.95)
	(b) Consumption of raw materials and packing materials	2,399.09	1,504.77	2,399.09	2,834.75	7,604.40
	(c) Purchase of traded goods	3,148.44	2,098.37	3,148.44	4,121.18	11,681.17
	(d) Employees cost	3,353.62	3,032.10	3,353.62	5,712.60	15,049.76
	(e) Depreciation	172.74	175.79	172.74	333.40	881.28
	(f) Other expenditure	3,727.46	3,714.61	3,727.46	7,372.11	16,074.49
	(g) Total	11,409.73	10,087.13	11,409.73	19,534.47	49,932.15
3	<b>Profit from operations before other income, interest &amp; exceptional items (1-2)</b>	2,338.50	1,004.06	2,338.50	1,347.51	9,470.35
4	Other income	150.27	106.68	150.27	165.32	628.14
5	<b>Profit before interest &amp; exceptional items (3+4)</b>	2,488.77	1,110.74	2,488.77	1,512.83	10,098.49
6	Interest	-	-	-	-	-
7	<b>Profit after interest but before exceptional items (5-6)</b>	2,488.77	1,110.74	2,488.77	1,512.83	10,098.49
8	Exceptional items	-	-	-	-	-
9	<b>Profit from ordinary activities before tax (7+8)</b>	2,488.77	1,110.74	2,488.77	1,512.83	10,098.49
10	Tax expense	813.95	379.29	813.95	519.98	3,685.52
11	<b>Net profit from ordinary activities after tax (9-10)</b>	1,674.82	731.45	1,674.82	992.85	6,412.97
12	Extraordinary item	-	-	-	-	-
13	<b>Net profit for the period (11-12)</b>	1,674.82	731.45	1,674.82	992.85	6,412.97
14	<b>Paid-up equity share capital</b> (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	<b>Reserves excluding revaluation reserves as per the balance sheet of previous accounting year</b>	-	-	-	-	17,468.96
16	<b>Basic and diluted earnings (Rs) per share (not annualised)</b>	6.70	2.93	6.70	3.97	25.65
17	<b>Public shareholding</b>					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	<b>Promoters and promoter group shareholding</b>					
	<b>a) Pledged / Encumbered</b>					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	<b>b) Non-encumbered</b>					
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%



**Notes:**

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 8 August 2011.
- Status of investor complaints: a) Pending as on 1 April 2011 - NIL b) Received during the quarter - NIL c) Disposed off during the quarter - NIL d) Pending as on 30 June 2011 - NIL.
- The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 30 June 2011 are for a 3 months period, while the corresponding figures are for a 6 months period and hence not strictly comparable.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.

**SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED**

Sl No.	Particulars	Rs. in lakhs				
		3 months ended 30.06.2011	3 months ended 30.6.2010	Year to date figure for 3 months ended 30.06.2011	Year to date figure for 6 months ended 30.06.2010	Previous accounting year (15 months period) ended 31.03.2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Segment Revenue</b>					
	(a) Healthcare	12,947.86	10,600.98	12,947.86	19,834.62	57,464.43
	(b) Others	806.41	495.59	806.41	1,057.97	1,966.30
	<b>Total</b>	<b>13,754.27</b>	<b>11,096.57</b>	<b>13,754.27</b>	<b>20,892.59</b>	<b>59,430.73</b>
	Less: Inter-segment Revenue	-	-	-	-	-
	<b>Net Income From Operations</b>	<b>13,754.27</b>	<b>11,096.57</b>	<b>13,754.27</b>	<b>20,892.59</b>	<b>59,430.73</b>
2	<b>Segment Results</b>					
	Profit before tax and interest					
	(a) Healthcare	2,317.06	1,008.65	2,317.06	1,349.53	9,386.50
	(b) Others	27.48	0.79	27.48	8.59	112.08
	<b>Total</b>	<b>2,344.54</b>	<b>1,009.44</b>	<b>2,344.54</b>	<b>1,358.12</b>	<b>9,498.58</b>
	Add: Other Income	144.23	101.30	144.23	154.71	599.91
	Less: Interest	-	-	-	-	-
	<b>Total Profit Before Tax</b>	<b>2,488.77</b>	<b>1,110.74</b>	<b>2,488.77</b>	<b>1,512.83</b>	<b>10,098.49</b>
3	<b>Capital Employed</b>					
	(a) Healthcare	15,240.58	9,400.05	15,240.58	9,400.05	12,122.33
	(b) Others	637.20	90.79	637.20	90.79	644.20
	(c) Unallocated	3,766.00	5,963.49	3,766.00	5,963.49	5,202.43
	<b>Total</b>	<b>19,643.78</b>	<b>15,454.33</b>	<b>19,643.78</b>	<b>15,454.33</b>	<b>17,968.96</b>

**Notes:**

- Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 30 June 2011 are for a 3 months period, while the corresponding figures are for a 6 months period and hence not strictly comparable.

By Order of the Board of Directors  
For ASTRAZENCA PHARMA INDIA LIMITED

Place: Bangalore  
Dated: 8 August 2011

Anandh Balasundaram  
Managing Director